Cancer

EXACT Sciences Announces First Quarter 2007 Results

Published in Patient Care Law Weekly, May 13th, 2007

EXACT Sciences Corporation (NASDAQ: EXAS) announced its financial results for the first quarter ended March 31, 2007.

For the quarter ended March 31, 2007, total revenues of $1.2 million were equal to the total revenues for the quarter ended March 31, 2006. These revenues primarily reflect the amortization of up-front license fee payments from Laboratory Corporation of America(R) Holdings (LabCorp(R)) and, to a lesser extent, royalties on LabCorp's sales of PreGen-Plus(TM) (LabCorp's colon cancer testing service) and sales of Effipure(TM) units to LabCorp. Net loss for the quarter ended March 31, 2007 decreased to $1.9 million, or $0.07 per share, compared to a net loss...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Patient Care Law Weekly

Source: Patient Care Law Weekly (2007-05-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry